Cure8 research brief
An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.
Adults newly diagnosed with Crohn's disease, gastroenterologists and IBD clinicians, and researchers interested in risk stratification tools.
The PreMiCC score uses variables available at diagnosis (age, CRP, presence of perianal disease, endoscopic severity, and complications) and was applied to 342 patients followed for an average of nine years. A lower score (≤2) was associated with a higher chance of a mild disease course and lower rates of treatment escalation and surgery.
How people might use this PreMiCC could help clinicians and patients discuss early risk stratification and guide monitoring or treatment decisions, but it does not replace individualized clinical judgment.
This report is a single-center retrospective external validation with moderate discrimination (AUC ~0.71). Although follow-up was long, results may not generalize to all settings; prospective validation would strengthen confidence.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
